Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Date:5/15/2008

KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that data from several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, as well as boceprevir, the company's investigational oral HCV protease inhibitor, will be presented at the 39th annual Digestive Disease Week (DDW) meeting to be held at the San Diego Convention Center, May 17-22.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States.

Clinical investigators will present findings from several PEGINTRON studies evaluating patient response to therapy at important treatment milestones, an approach that is aimed at individualizing treatment for patients to help improve outcomes. In particular, Schering-Plough is exploring unique treatment strategies for patients with more difficult-to-treat forms of the disease, such as patients who were nonresponders to previous therapy.

Schering-Plough also is exploring novel therapeutic approaches to treating hepatitis C with boceprevir, its investigational oral HCV protease inhibitor currently in Phase II clinical development. The final results of a Phase II dose-finding study of boceprevir with or without ribavirin in patients who were "null" responders to previous peginterferon and ribavirin combination therapy will be presented.

Key Data Presentations
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
3. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
7. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:9/30/2014)... Keystone Symposia will convene the first conference of ... Global Health Series on "The Modes of Action ... immediately following the conclusion of the Grand Challenges Meeting ... of the Keystone Symposia Global Health Series, supported by ... funded travel awards for 36 investigators from developing countries ...
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... Calif., Sept. 30, 2014 Research by UC Irvine ... functions, shedding light on a vital process that determines ... In the online version of Nature Immunology , ... and other Institute for Immunology colleagues describe a critical ... released into the bloodstream. , A T cell is ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... 30, 2014 Elevate , the latest ... better in and out of the gym by providing natural ... the attention of Shane Michaels, prompting an investigative review. ... the reason most people simply just don’t have the ability ... focused at work, getting the motivation to finish a project, ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... Authorizations and Reduces DenialsGREENWOOD VILLAGE, Colo., March 25 ... cycle solutions for the healthcare industry, today announced ... and denial prevention product for hospitals. Missing authorizations ... 15 percent of all payer-denied claims, and can ...
... Inc., the largest privately held spinal implant manufacturer ... MicroFuse(TM) ST Granules, a unique resorbable polymer bone ... MicroFuse(TM) technology utilizes proprietary combinations of poly (lactic ... patented microsphere process to deliver up to twelve ...
... 50 raises odds almost 4-fold , , WEDNESDAY, March 25 (HealthDay ... fourfold increased risk of melanoma in women under the age ... York University School of Medicine. , Identification of this variation ... test to identify women at high risk for the deadly ...
... ACell, Inc. and its founder, Alan Spievack, MD, ... Spievack described how his severed finger grew back after ... technology is a naturally occurring bioscaffold derived from porcine ... it is resorbed and replaced with new native tissue ...
... Dr. Ching-Hua Wang, Chair of Biology, Geology and Nursing, ... California State University Channel Islands , was recently awarded ... Medicine (CIRM) as a part of their Bridges to Stem ... to receive funding from the program. , , ...
... "Today was a monumental day on Capitol Hill ... long-term services and supports.We commend the Senate Finance Committee ... in this year,s health care reform. Long-term services and ... America,s health care crisis. The needs are great. The ...
Cached Medicine News:Health News:Recondo Technology Announces Authorization and Denial Prevention Software Service 2Health News:Globus Medical's MicroFuse(TM) Technology Engineered for Optimal Strength and Porosity 2Health News:Gene Test May ID Younger Women at Risk for Melanoma 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 3Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 2Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 3
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and negative ... inoculation. With these slides, perform QC and ... enhance their education and training programs by ... interpretation, all on one slide! KWIK-QC slides ...
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: